ArticleFrontiers in molecular biosciences2024
Integrated multi-omics analysis describes immune profiles in ischemic heart failure and identifies PTN as a novel biomarker.
Article in Frontiers in molecular biosciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Article
- MicroRNAs in Heart Failure Pathogenesis and Progression: Mechanistic Control, Biomarker Potential, and Translational Perspectives.Life (Basel, Switzerland) · 2026Review
- Zinc and its binding proteins: essential roles and therapeutic potential.Archives of toxicology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Heart failure is a leading global cause of mortality, with ischemic heart failure (IHF) being a major contributor. IHF is primarily driven by coronary artery disease, and its underlying mechanisms are not fully understood, particularly the role of immune responses and inflammation in cardiac muscle remodeling. This study aims to elucidate the immune landscape of heart failure using multi-omics data to identify biomarkers for preventing cardiac fibrosis and disease progression. Methods: We utilized multi-omics data to elucidate the intricate immune landscape of heart failure at various regulatory levels. Given the substantial size of our transcriptomic dataset, we used diverse machine learning techniques to identify key mRNAs. For smaller datasets such as our proteomic dataset, we applied multilevel data cleansing and enhancement using principles from network biology. This comprehensive analysis led to the development of a scalable, integrated -omics analysis pipeline. Results: Pleiotrophin (PTN) had shown significant upregulation in multiple datasets and the activation of various molecules associated with dysplastic cardiac remodeling. By synthesizing these data with experimental validations, PTN was identified as a potential biomarker. Discussion: The present study not only provides a comprehensive perspective on immune dynamics in IHF but also offers valuable insights for the identification of biomarkers, discovery of therapeutic targets, and development of drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.